Axsome Therapeutics FY Conference Summary Company Overview - **Company**: Axsome Therapeutics (NasdaqGM:AXSM) - **Date of Conference**: March 02, 2026 - **Key Personnel**: COO Mark Jacobson, CFO Nick Pizzie Core Business and Financial Performance - **AUVELITY Performance**: Generated $155 million in the last quarter, annualizing over $600 million after 13 quarters from launch [3][4] - **Sales Force Expansion**: Plans to increase field force from 300 to 600 representatives to enhance market penetration, particularly in anticipation of Alzheimer's disease agitation [3][4] - **Operating Leverage**: Revenues outpaced operating expenses by a ratio of 3:1 in 2025, with expectations for continued leverage in 2026 [4] Product Pipeline and Development - **Robust Pipeline**: Currently has 5 product candidates across 9 indications, with AXS-05 for Alzheimer's disease agitation being a key focus [5] - **PDUFA Date**: AXS-05 has a PDUFA date set for April 30, 2026, with pre-launch activities already underway [5][12] - **Clinical Trials**: Positive results from randomized withdrawal studies and head-to-head placebo-controlled studies for AXS-05, with significant safety data collected [15][16] Market Insights - **Market Penetration**: Currently at 0.2% of the total antidepressant market, indicating substantial growth potential [8] - **Patient Demographics**: Over 7 million Alzheimer's patients in the U.S., with an estimated 70% experiencing agitation, representing a significant treatment opportunity [20] - **Direct-to-Consumer Campaign**: Launched a national DTC campaign in September, with plans to continue through 2026, aiming to enhance product adoption [10][11] Competitive Landscape - **Comparison with Rexulti**: Acknowledged as the only approved product for Alzheimer's agitation, but differences in mechanism and sales strategy noted [31][32] - **Market Access**: Anticipated 100% coverage in government channels for Alzheimer's agitation, similar to MDD, which could facilitate script writing [34] Additional Products and Future Opportunities - **Simbravo Launch**: Targeted approach with a sales team focused on headache centers, showing early positive feedback [35][36] - **AXS-12 for Narcolepsy**: NDA submission expected soon, with peak sales potential estimated between $500 million to $1 billion [40][42] - **Sunosi Expansion**: Positive Phase 3 data in adult ADHD, with plans for pediatric studies, indicating a significant market opportunity [43][44] - **AXS-14 for Fibromyalgia**: Currently conducting a new study following an RTF from the FDA, with expectations for compelling data in an underserved market [51][53] Conclusion - Axsome Therapeutics is positioned for significant growth with a robust pipeline and strategic expansions in sales force and market access. The upcoming PDUFA date for AXS-05 and ongoing clinical trials for other products highlight the company's commitment to addressing unmet medical needs in various therapeutic areas.

Summary of Alkermes Conference Call Company Overview - **Company**: Alkermes - **Event**: 2026 TD Cowen Healthcare Conference - **Key Speaker**: Richard Pops, Chairman and CEO Industry Focus - **Primary Industry**: Sleep Medicine - **Key Products**: Alixorexton, LUMRYZ, Avadel acquisition Core Points and Arguments 1. **Business Transition**: Alkermes has undergone significant changes in 2025, solidifying its position in the sleep medicine market, particularly with the orexin franchise and the acquisition of Avadel [2][3] 2. **Market Position**: The company is now a major player in the sleep medicine market, preparing for the launch of alixorexton, supported by a strong and cash-generative base business [3] 3. **Acquisition Rationale**: The acquisition of Avadel was strategic, enhancing the company's presence in sleep centers and preparing for the alixorexton launch, which is expected to shift the launch curve positively [4][7] 4. **Unmet Needs in Narcolepsy**: There is a significant gap between the prevalence of narcolepsy (approximately 200,000 patients in the U.S.) and those treated (about 80,000), indicating a large market opportunity [15] 5. **Orexin Compounds**: The company is investigating the ideal dosing for orexin agonists, with promising data from Phase 2 studies indicating safety and efficacy [17][18] 6. **Phase 3 Program**: Alkermes is initiating a Phase 3 program with three studies focused on NT-1 and NT-2, with primary endpoints including the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS) [24][25] 7. **Cognitive and Fatigue Outcomes**: The company has observed significant improvements in cognitive complaints and fatigue in patients, which are critical for treatment success [56][57] Additional Important Content 1. **Base Business Strength**: Alkermes has transformed from a royalty-based business to a proprietary products business, with expectations of $1.4 billion from proprietary products in 2026 [59][60] 2. **Commercial Strategy**: The acquisition of Avadel is expected to broaden the commercial portfolio and increase profitability, allowing for aggressive investment in the pipeline [60][61] 3. **Future Opportunities**: Alkermes is exploring additional indications for orexin drugs, including ADHD and fatigue, with initial proof of concept data expected soon [46][48] 4. **Side Effect Profile**: The orexin compounds have a mild to moderate side effect profile, with insomnia being the most common, which tends to diminish over time [39][40] 5. **Business Development**: The company is open to tuck-in business development deals that leverage its clinical and scientific capabilities but is currently focused on executing its late-stage and earlier-stage programs [63][64] This summary encapsulates the key points discussed during the conference call, highlighting Alkermes' strategic direction, market opportunities, and product development plans.

Core Viewpoint - Avadel Pharmaceuticals has completed patient enrollment in the REVITALYZ Phase 3 trial for LUMRYZ, an extended-release oral suspension of sodium oxybate, aimed at treating idiopathic hypersomnia (IH) [2][5]. Group 1: Trial Details - REVITALYZ is a double-blind, placebo-controlled, randomized withdrawal trial assessing the efficacy and safety of LUMRYZ administered as a once-at-bedtime dose for IH patients [3]. - The primary objective is to demonstrate a reduction in daytime sleepiness, measured by the change in total score on the Epworth Sleepiness Scale (ESS) at Week 14 [4]. - Secondary endpoints will evaluate additional efficacy parameters, including patient and clinician impressions, severity of IH, and functional outcomes of sleep [4]. Group 2: Market Need and Potential - Idiopathic hypersomnia is a serious sleep disorder affecting approximately 40,000 diagnosed patients in the U.S., characterized by extreme difficulty waking up and persistent daytime sleepiness [6]. - The approval of LUMRYZ could provide a valuable treatment option for IH patients, as current treatments are limited [4][5]. Group 3: Background on LUMRYZ - LUMRYZ was approved by the FDA on May 1, 2023, as the first and only once-at-bedtime treatment for cataplexy or excessive daytime sleepiness in adults with narcolepsy [7]. - The drug received Orphan Drug Designation for IH in June 2025, indicating its potential clinical superiority over existing treatments [9][10]. - LUMRYZ's once-nightly dosing regimen is designed to improve patient care by avoiding nocturnal arousal for a second dose [9].

Core Insights - Harmony Biosciences Holdings, Inc. (HRMY) shares fell by 16.56% on September 24 following the announcement of the failure of the late-stage RECONNECT study for ZYN002 in Fragile X syndrome (FXS) [1][2] - The RECONNECT study was a randomized, double-blind, placebo-controlled trial aimed at assessing the efficacy and safety of ZYN002, a transdermal gel cannabidiol for patients aged 3 to under 30 years with FXS [1][2] - The study did not meet its primary endpoint of improving social avoidance, attributed to a higher-than-expected placebo response rate [2] Company Performance - Year-to-date, HRMY has experienced a 22.2% decline, contrasting with a 5.3% gain in the industry [3] - The company's lead drug, Wakix (pitolisant), generated revenues of $200.5 million in the second quarter [5][7] - HRMY plans to initiate phase III registrational trials for a high dose of pitolisant in narcolepsy and idiopathic hypersomnia in the fourth quarter of 2025 [5][7] Pipeline Expansion - HRMY has broadened its pipeline into rare epilepsy through the acquisition of Epygenix Therapeutics, adding EPX-100 and EPX-200 to its portfolio [6][7] - EPX-100 is currently in phase III registrational trials for Dravet Syndrome and Lennox-Gastaut Syndrome, while EPX-200 is in the pre-IND phase for developmental and epileptic encephalopathies [6]

Core Insights - Jazz Pharmaceuticals presented new real-world evidence and Phase 4 data at World Sleep 2025 and the Psych Congress, highlighting the effectiveness of Xywav in treating narcolepsy and idiopathic hypersomnia [1][2][6] Group 1: Clinical Trial Results - The Phase 4 DUET trial demonstrated that low-sodium Xywav significantly improves daytime and nighttime symptoms in adults with narcolepsy or idiopathic hypersomnia [1][6] - Participants in the DUET trial experienced fewer awakenings and improved sleep measures, indicating enhanced sleep quality [6] - The analysis of the DUET data showed reduced sleep inertia and improved alertness among participants receiving optimized Xywav treatment [6] Group 2: Real-World Evidence - Real-world analyses indicated that individuals with narcolepsy or idiopathic hypersomnia face elevated risks of cardiovascular and cardiometabolic conditions, emphasizing the need for sodium intake reduction [6][8] - The data presented at the congresses reinforce the importance of understanding treatment impacts on both daytime and nighttime symptoms for patients [2][6] Group 3: Xywav Overview - Xywav is the only low-sodium oxybate approved by the FDA for treating cataplexy and excessive daytime sleepiness in patients aged 7 and older with narcolepsy [11] - It is also the first FDA-approved treatment for idiopathic hypersomnia in adults, addressing multiple symptoms including excessive daytime sleepiness and sleep inertia [12] - Xywav has a significantly lower sodium content compared to other oxybate therapies, providing a safer option for patients sensitive to sodium intake [11][12] Group 4: Company Positioning - Jazz Pharmaceuticals aims to leverage both Phase 4 clinical trials and real-world evidence to enhance understanding of sleep disorders and improve treatment outcomes [2][40] - The company is dedicated to developing innovative therapies for serious diseases, with a focus on sleep disorders and oncology [40][41]